Advertisement

Closed-Loop Insulin Delivery Using a Subcutaneous Glucose Sensor and Intraperitoneal Insulin Delivery

Feasibility study testing a new model for the artificial pancreas

  1. Eric Renard, MD, PHD1,
  2. Jerome Place, MSC1,
  3. Martin Cantwell, BSC2,
  4. Hugues Chevassus, PHARMD3 and
  5. Cesar C. Palerm, PHD2
  1. 1Endocrinology Department, Le Centre Hospitalier Universitaire Montpellier and Unité Mixte de Recherche Centre National de la Recherche Scientifique 5232, University of Montpellier, Montpellier, France;
  2. 2Medtronic Diabetes, Northridge, California;
  3. 3INSERM Clinical Investigation Centre 001, Le Centre Hospitalier Universitaire Montpellier, Montpellier, France.
  1. Corresponding author: Eric Renard, renard.amtim{at}wanadoo.fr.

Abstract

OBJECTIVE Attempts to build an artificial pancreas by using subcutaneous insulin delivery from a portable pump guided by an subcutaneous glucose sensor have encountered delays and variability of insulin absorption. We tested closed-loop intraperitoneal insulin infusion from an implanted pump driven by an subcutaneous glucose sensor via a proportional-integral-derivative (PID) algorithm.

RESEARCH DESIGN AND METHODS Two-day closed-loop therapy (except for a 15-min premeal manual bolus) was compared with a 1-day control phase with intraperitoneal open-loop insulin delivery, according to randomized order, in a hospital setting in eight type 1 diabetic patients treated by implanted pumps. The percentage of time spent with blood glucose in the 4.4–6.6 mmol/l range was the primary end point.

RESULTS During the closed-loop phases, the mean ± SEM percentage of time spent with blood glucose in the 4.4–6.6 mmol/l range was significantly higher (39.1 ± 4.5 vs. 27.7 ± 6.2%, P = 0.05), and overall dispersion of blood glucose values was reduced among patients. Better closed-loop glucose control came from the time periods excluding the two early postprandial hours with a higher percentage of time in the 4.4–6.6 mmol/l range (46.3 ± 5.3 vs. 28.6 ± 7.4, P = 0.025) and lower mean blood glucose levels (6.9 ± 0.3 vs. 7.9 ± 0.6 mmol/l, P = 0.036). Time spent with blood glucose <3.3 mmol/l was low and similar for both investigational phases.

CONCLUSIONS Our results demonstrate the feasibility of intraperitoneal insulin delivery for an artificial β-cell and support the need for further study. Moreover, according to a semiautomated mode, the features of the premeal bolus in terms of timing and amount warrant further research.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Received June 12, 2009.
    • Accepted October 10, 2009.
| Table of Contents

This Article

  1. Diabetes Care January 2010 vol. 33 no. 1 121-127
  1. All Versions of this Article:
    1. dc09-1080v1
    2. 33/1/121 most recent
Advertisement